PriceTargets.com logo

AnaptysBio - ANAB Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $59.30
  • Forecasted Upside: 36.95%
  • Number of Analysts: 12
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$43.30 As of 12/4/2025 05:00 PM ET
▼ -0.46 (-1.05%)

This chart shows the closing price for ANAB by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New AnaptysBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANAB

Analyst Price Target is $59.30
▲ +36.95% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for AnaptysBio in the last 3 months. The average price target is $59.30, with a high forecast of $100.00 and a low forecast of $20.00. The average price target represents a 36.95% upside from the last price of $43.30.

This chart shows the closing price for ANAB for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 contributing investment analysts is to moderate buy stock in AnaptysBio. This rating has held steady since February 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/24/2025WedbushReiterated RatingOutperform ➝ Outperform$50.00
11/24/2025HC WainwrightLower TargetBuy ➝ Buy$52.00 ➝ $51.00
11/11/2025BarclaysLower TargetOverweight ➝ Overweight$83.00 ➝ $70.00
11/11/2025HC WainwrightLower TargetBuy ➝ Buy$59.00 ➝ $52.00
11/10/2025WedbushReiterated RatingOutperform ➝ Outperform$50.00
11/10/2025Truist FinancialBoost TargetHold ➝ Hold$20.00 ➝ $36.00
11/5/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$51.00 ➝ $81.00
11/5/2025GuggenheimBoost TargetBuy ➝ Buy$90.00 ➝ $100.00
10/29/2025Stifel NicolausBoost TargetBuy ➝ Buy$55.00 ➝ $80.00
10/15/2025WedbushBoost TargetOutperform ➝ Outperform$45.00 ➝ $70.00
10/13/2025BarclaysInitiated CoverageOverweight$78.00
10/13/2025BarclaysInitiated CoverageOverweight$78.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/30/2025HC WainwrightBoost TargetBuy ➝ Buy$38.00 ➝ $59.00
9/30/2025WedbushReiterated RatingOutperform ➝ Outperform$45.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/16/2025WedbushReiterated RatingOutperform$45.00
8/12/2025UBS GroupReiterated RatingNeutral ➝ Neutral$18.00 ➝ $20.00
8/7/2025WedbushBoost TargetOutperform ➝ Outperform$40.00 ➝ $45.00
7/24/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$42.00 ➝ $80.00
6/4/2025HC WainwrightUpgradeNeutral ➝ Buy$22.00 ➝ $38.00
5/29/2025WedbushReiterated RatingOutperform$40.00
5/28/2025GuggenheimReiterated RatingBuy ➝ Buy$54.00 ➝ $90.00
5/6/2025GuggenheimBoost TargetBuy ➝ Buy$52.00 ➝ $54.00
5/1/2025WedbushReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
3/26/2025Johnson RiceReiterated RatingBuy ➝ Buy
3/5/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$36.00 ➝ $42.00
3/4/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.00
3/3/2025GuggenheimReiterated RatingBuy ➝ Buy
2/13/2025Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$40.00 ➝ $51.00
2/12/2025WedbushReiterated RatingOutperform$40.00
2/4/2025Wolfe ResearchInitiated CoverageOutperform$25.00
2/4/2025HC WainwrightReiterated RatingNeutral ➝ Neutral$19.00 ➝ $19.00
2/3/2025Wolfe ResearchUpgradeStrong-Buy
2/3/2025WedbushReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00
12/19/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$66.00 ➝ $36.00
12/18/2024Truist FinancialLower TargetHold ➝ Hold$30.00 ➝ $20.00
12/12/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$56.00 ➝ $40.00
12/12/2024GuggenheimLower TargetBuy ➝ Buy$90.00 ➝ $36.00
12/11/2024WedbushReiterated RatingOutperform$42.00 ➝ $40.00
12/11/2024HC WainwrightDowngradeBuy ➝ Neutral$52.00 ➝ $19.00
12/2/2024BTIG ResearchDowngradeBuy ➝ Neutral
11/14/2024WedbushReiterated RatingOutperform$42.00
11/12/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$75.00 ➝ $66.00
11/6/2024HC WainwrightLower TargetBuy ➝ Buy$55.00 ➝ $52.00
11/6/2024WedbushReiterated RatingOutperform$42.00
10/31/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
10/30/2024UBS GroupBoost TargetNeutral ➝ Neutral$23.00 ➝ $33.00
10/21/2024GuggenheimBoost TargetBuy ➝ Buy$75.00 ➝ $90.00
9/26/2024WedbushReiterated RatingOutperform ➝ Outperform$42.00 ➝ $42.00
8/15/2024Truist FinancialBoost TargetHold ➝ Hold$20.00 ➝ $30.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
8/7/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$69.00 ➝ $75.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$55.00 ➝ $55.00
7/22/2024HC WainwrightInitiated CoverageBuy$55.00
7/19/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$29.00 ➝ $69.00
5/10/2024WedbushReiterated RatingOutperform ➝ Outperform$34.00
4/16/2024Leerink PartnrsReiterated RatingOutperform
4/16/2024Leerink PartnersInitiated CoverageOutperform$47.00
4/11/2024Wells Fargo & CompanyInitiated CoverageOverweight$56.00
4/1/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$30.00 ➝ $28.00
3/12/2024WedbushUpgradeNeutral ➝ Outperform$20.00 ➝ $34.00
2/26/2024BTIG ResearchInitiated CoverageBuy$55.00
2/21/2024Stifel NicolausInitiated CoverageBuy$50.00
2/16/2024Piper SandlerInitiated CoverageOverweight$80.00
11/29/2023WedbushReiterated RatingNeutral ➝ Neutral$20.00
11/3/2023WedbushBoost TargetNeutral ➝ Neutral$18.00 ➝ $20.00
11/2/2023UBS GroupLower TargetNeutral ➝ Neutral$28.00 ➝ $21.00
8/8/2023WedbushLower TargetNeutral ➝ Neutral$29.00 ➝ $26.00
5/22/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$31.00 ➝ $30.00
5/18/2023TD CowenInitiated CoverageOutperform
5/12/2023GuggenheimBoost Target$44.00 ➝ $45.00
4/12/2023JPMorgan Chase & Co.Lower TargetUnderweight$32.00 ➝ $31.00
1/6/2023Raymond James FinancialDowngradeOutperform ➝ Market Perform
11/18/2022JPMorgan Chase & Co.Boost TargetUnderweight$24.00 ➝ $32.00
11/9/2022WedbushBoost Target$21.00 ➝ $32.00
11/9/2022Raymond James FinancialBoost TargetOutperform$30.00 ➝ $38.00
11/1/2022GuggenheimUpgradeNeutral ➝ Buy$44.00
9/19/2022HC WainwrightReiterated RatingBuy$35.00
9/13/2022Truist FinancialDowngradeBuy ➝ Hold$50.00 ➝ $28.00
9/6/2022WedbushLower Target$24.00
9/1/2022Raymond James FinancialLower Target$35.00 ➝ $30.00
8/31/2022Raymond James FinancialInitiated CoverageOutperform$35.00
3/22/2022GuggenheimDowngradeBuy ➝ Neutral
3/14/2022WedbushReiterated RatingNeutral
3/7/2022WedbushLower TargetNeutral$35.00 ➝ $33.00
3/7/2022HC WainwrightBoost TargetBuy$43.00 ➝ $46.00
10/26/2021HC WainwrightReiterated RatingBuy$44.00
10/26/2021WedbushBoost TargetNeutral$25.00 ➝ $32.00
10/4/2021HC WainwrightReiterated RatingBuy$43.00
9/27/2021HC WainwrightReiterated RatingBuy$43.00
8/18/2021WedbushBoost TargetPositive ➝ Neutral$20.00 ➝ $25.00
8/10/2021HC WainwrightReiterated RatingBuy$43.00
6/22/2021HC WainwrightInitiated CoverageBuy$43.00
5/20/2021UBS GroupInitiated CoverageNeutral$29.00
3/16/2021Truist FinancialUpgradeHold ➝ Buy$27.00 ➝ $34.00
3/15/2021WedbushReiterated RatingOutperform ➝ Neutral
3/9/2021WedbushDowngradeOutperform ➝ Neutral
3/8/2021JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight
2/11/2021JPMorgan Chase & Co.UpgradeUnderweight ➝ Overweight$19.00 ➝ $40.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
5/8/2025
  • 29 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 6 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 14 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 17 very positive mentions
  • 19 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 10 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 20 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 20 very positive mentions
  • 23 positive mentions
  • 8 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

AnaptysBio logo
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More

Today's Range

Now: $43.30
Low: $42.63
High: $45.32

50 Day Range

MA: $35.31
Low: $23.27
High: $43.76

52 Week Range

Now: $43.30
Low: $12.21
High: $45.32

Volume

591,640 shs

Average Volume

743,185 shs

Market Capitalization

$1.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.29

Frequently Asked Questions

What sell-side analysts currently cover shares of AnaptysBio?

The following Wall Street research analysts have issued stock ratings on AnaptysBio in the last twelve months: Barclays PLC, Guggenheim, HC Wainwright, Johnson Rice, JPMorgan Chase & Co., Stifel Nicolaus, Truist Financial Corporation, UBS Group AG, Wall Street Zen, Wedbush, Weiss Ratings, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for ANAB.

What is the current price target for AnaptysBio?

0 Wall Street analysts have set twelve-month price targets for AnaptysBio in the last year. Their average twelve-month price target is $59.30, suggesting a possible upside of 37.0%. Guggenheim has the highest price target set, predicting ANAB will reach $100.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $20.00 for AnaptysBio in the next year.
View the latest price targets for ANAB.

What is the current consensus analyst rating for AnaptysBio?

AnaptysBio currently has 1 sell rating, 2 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANAB.

What other companies compete with AnaptysBio?

Other companies that are similar to AnaptysBio include Akero Therapeutics, Crinetics Pharmaceuticals, Scholar Rock, Immunovant and Arcellx. Learn More about companies similar to AnaptysBio.

How do I contact AnaptysBio's investor relations team?

AnaptysBio's physical mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 362-6295 and its investor relations email address is [email protected]. The official website for AnaptysBio is www.anaptysbio.com. Learn More about contacing AnaptysBio investor relations.